Caroline Humer

New York

Health Editor at Reuters

health & pharma, for Reuters

Featured in: Favicon

reuters.com

Articles

Exclusive-FDA fires most negotiators for pharma user fee talks, sources say

1 week ago | today.westlaw.com | Maggie Fick |Jamie Freed |Marisa Taylor |Caroline Humer

LONDON/WASHINGTON (Reuters) -The U.S. Food and Drug Administration's mass layoffs included senior negotiators in talks with the pharmaceutical industry over renewing the user fee programs that fund the regulator's drug review system, six sources...
US measles battle hindered by confusion over health secretary response

2 weeks ago | today.westlaw.com | Bill Berkrot |Caroline Humer |Julie Steenhuysen

CHICAGO (Reuters) -U.S. pediatricians and infectious disease experts say the fight against rising measles cases nationwide is being hampered by a lack of forceful advocacy for vaccination from government health officials and statements on unproven...
Exclusive-FDA staff struggle to meet product review deadlines after DOGE layoffs

4 weeks ago | today.westlaw.com | Bill Berkrot |Michele Gershberg |Patrick Wingrove |Caroline Humer

(Reuters) -Some U.S. health regulators who review medical devices and tobacco products for safety and efficacy are struggling to meet deadlines mandated by Congress due to Trump administration layoffs, three scientists working on the projects told...
Trump healthcare price transparency order may not bring intended relief to patients

4 weeks ago | today.westlaw.com | Amina Niasse |Bill Berkrot |Caroline Humer

NEW YORK (Reuters) -A Trump administration executive order intended to provide patients with the prices from hospitals and insurers they need to shop around may prove ineffective because of the huge amount of unorganized data it will generate,...
Gene therapy loses luster as investors eye quicker returns from weight-loss drugs

1 month ago | kfgo.com | Deena Beasley |Caroline Humer

By Deena Beasley(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward sectors like obesity and cancer, as sales for some of the new treatments fall short. In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene therapy for hemophilia priced at $3.5 million per patient.
Trump Medicare nominee Dr Oz may have underpaid taxes, Senate Democrats say

1 month ago | today.westlaw.com | David Gregorio |Ahmed Aboulenein |Caroline Humer

WASHINGTON (Reuters) -Dr. Mehmet Oz, the celebrity physician nominated by President Donald Trump to oversee the government's Medicare and Medicaid health plans, appears to have underpaid his own Medicare taxes by over $400,000, Democratic staffers on...
Trump's NIH pick Bhattacharya's challenges to include research funding cuts

1 month ago | today.westlaw.com | Bill Berkrot |Ahmed Aboulenein |Caroline Humer

WASHINGTON (Reuters) -President Donald Trump's nominee to lead the National Institutes of Health, vocal U.S. COVID-19 policy critic Dr. Jay Bhattacharya, is widely expected to advance after facing questions on Wednesday in a Senate committee...
Lilly offers weight-loss drugs in vials at a discount to fight competition

1 month ago | today.westlaw.com | Sriparna Roy |Bill Berkrot |Patrick Wingrove |Caroline Humer

(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from compounding pharmacies and rival Novo Nordisk.
Kennedy to take top US health job after Senate confirmation

2 months ago | today.westlaw.com | Bill Berkrot |Ahmed Aboulenein |Caroline Humer

WASHINGTON (Reuters) -Robert F. Kennedy Jr, a vaccine critic who endorsed President Donald Trump after abandoning his own presidential bid, was confirmed by the U.S. Senate as Secretary of Health and Human Services on Thursday, overcoming resistance...
Trump signs executive order withdrawing from the World Health Organization

Jan 20, 2025 | dzrh.com.ph | Patrick Wingrove |Caroline Humer |Shri Navaratnam

NEW YORK, Jan 20 (Reuters) - The United States will exit the World Health Organization, President Donald Trump said on Monday, saying the global health agency had mishandled the COVID-19 pandemic and other international health crises. Trump said the WHO had failed to act independently from the "inappropriate political influence of WHO member states" and required "unfairly onerous payments" from the U.S. that are disproportionate to the sums provided by other, larger countries, such as China.